Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04929184
Other study ID # HUM00194953
Secondary ID 1R21DC019429-01
Status Recruiting
Phase N/A
First received
Last updated
Start date April 4, 2022
Est. completion date June 2025

Study information

Verified date June 2024
Source University of Michigan
Contact Emily Garnett, PhD
Phone 734-232-3371
Email emilyog@umich.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This research is being done to better understand stuttering, specifically how people who stutter may process and/or produce speech. Eligible participants enrolled will complete a variety of computer and speech-based tasks on up to 2 visits.


Description:

The study team will update the record to include the secondary identification number once the NIH has released the funds.


Recruitment information / eligibility

Status Recruiting
Enrollment 140
Est. completion date June 2025
Est. primary completion date June 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Years to 65 Years
Eligibility Inclusion Criteria (adults who do not stutter): - 18-65 years old - English as primary language - Normal speech, language, hearing, cognition Exclusion criteria: (adults who do not stutter) - Personal or family history of stuttering - Major medical or psychiatric illness Inclusion criteria: (adults who stutter) - Aged 18-65 years - English as primary language - Normal speech, language, hearing, cognition (other than stuttering) - Currently stutters Exclusion criteria: (adults who stutter) - Speech therapy within the past year - Major medical or psychiatric illness Inclusion criteria: (children who do not stutter) - Aged 6 to 17 years - English as primary language - Normal speech, language, hearing, cognition Exclusion criteria: (children who do not stutter) - Personal or family history of stuttering - Major medical or psychiatric illness - Language/motor delay Inclusion criteria: (children who stutter) - Aged 6 to 17 years - English as primary language - Normal speech, language, hearing, cognition (other than stuttering) - Currently stutters Exclusion criteria: (children who stutter) - Major medical or psychiatric illness - Language/motor delay

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Speech and non-speech tasks
Participants will complete speech tasks such as listening to and/or producing speech and non-speech sounds.

Locations

Country Name City State
United States University of Michigan Ann Arbor Michigan
United States Michigan State University East Lansing Michigan

Sponsors (2)

Lead Sponsor Collaborator
University of Michigan National Institute on Deafness and Other Communication Disorders (NIDCD)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Phase locking value (PLV) - Session 1 speech tasks The degree of synchronization will be measured by computing the PLV between subject's produced speech and the heard speech. The PLV is a vector with a value between 0 and 1 that reflects the phase difference between two signals. Session 1 (up to 4 hours)
Primary Phase locking value (PLV) - Session 2 speech tasks The degree of synchronization will be measured by computing the PLV between subject's produced speech and the heard speech. The PLV is a vector with a value between 0 and 1 that reflects the phase difference between two signals. Session 2 is for adults only. Session 2 (up to 4 hours)
Secondary Phase locking value (PLV) - Non-speech tasks The degree of synchronization will be measured by computing the PLV between subject's produced response and the auditorily presented stimuli. The PLV is a vector with a value between 0 and 1 that reflects the phase difference between two signals. Session 1 (up to 4 hours)
See also
  Status Clinical Trial Phase
Suspended NCT01684657 - A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Asenapine With Flexible Dosing From 5mg to 20mg in Adults With Developmental Stuttering Phase 3
Not yet recruiting NCT05437627 - Computerized Based Analysis for Detection and Severity Assessment of Stuttering
Completed NCT02288598 - Enhancing Speech Fluency With Non-invasive Brain Stimulation in Developmental Stuttering N/A
Completed NCT00001602 - Genetic Factors Related to Stuttering N/A
Active, not recruiting NCT04082104 - Assessment of Stuttering Severity in Adults and Adolescences in Conversational and Narrative Contexts
Completed NCT04580966 - IBSR Intervention for Adults Who Stutter N/A
Recruiting NCT00148161 - Activity of the Auditory Cortex During Speech Perception and Speech Production in Stuttering N/A
Recruiting NCT05908123 - Exploring the Nature, Assessment and Treatment of Stuttering N/A
Completed NCT00001551 - Characteristics of Idiopathic Familial Speech Disorders N/A
Withdrawn NCT01315730 - The Effects of Tactile Speech Feedback on Stuttering Frequency Phase 1
Completed NCT00004991 - Study of Brain Activity During Speech Production and Speech Perception N/A
Recruiting NCT05286151 - Network Connectivity and Temporal Processing in Adolescents Who Stutter N/A
Completed NCT00001604 - Genetic Linkage Studies of Stuttering
Recruiting NCT00680303 - Spacing Lidcombe Program Clinic Visits Phase 2
Recruiting NCT00709072 - Follow-up of Children After Stuttering Treatment Phase 2
Completed NCT00830154 - A Study to Assess the Efficacy and Safety of Pagoclone for Adults With Stuttering Phase 2/Phase 3
Completed NCT03698539 - How Stuttering and Gestures Influence the Intelligibility of Individuals With Down Syndrome
Completed NCT04505696 - Providing Speech Therapy Awareness in Private Schools N/A
Terminated NCT00001308 - Central Mechanisms in Speech Motor Control Studied With H215O PET
Completed NCT01097161 - Stuttering and Apraxia of Speech: the Efficacy of an Intervention Program N/A